Loopholes in pharma pricing policy - Hindu Business Line
Hindu Business LineLoopholes in pharma pricing policyHindu Business LineSimilarly in the class of angiotensin II receptor antagonists (also used in high blood pressure), we have losartan potassium in the NLEM 2011 list but not candesartan, irbesartan, telmisartan, valsartan and olmesartan.
Teva Reports First Quarter 2012 Results - MarketWatch (press release)
Proactive Investors USA & CanadaTeva Reports First Quarter 2012 ResultsMarketWatch (press release)Products launched included escitalopram, modafinil, progesterone, irbesartan and irbesartan/HCTZ, quetiapine and olanzapine ODT.
Product launches, Cephalon acquisition drive Teva's Q1 revenues - Drug Store News
Product launches, Cephalon acquisition drive Teva's Q1 revenuesDrug Store News.
Strong Q1 for Sanofi ahead of challenging nine months - PMLiVE
The Star-Ledger - NJ.
Generic Plavix debuts in US - PMLiVE
Generic Plavix debuts in USPMLiVESanofi and BMS are weathering the impact of two major patent expiries each, with BMS set to lose US patent protection for $1.
us